Nvidia shares have fallen for the fourth consecutive session, marking a technical correction with a 15% decline from last month’s record high. After reaching a peak, the stock has traded mostly sideways before dropping below the 50-day moving average late last week, signaling potential consolidation. Investors are advised to monitor key support levels at around […]
The S&P 500 slid 0.4% on Tuesday, Sept. 17. Major U.S. equities indexes faltered as the Federal Reserve kicked off its final two-day policy meeting of 2024. The central bank is widely expected to announce a third consecutive interest rate cut on Wednesday afternoon. Investors are likely to scrutinize the language in the accompanying statement
U.S. equities experienced gains at midday in anticipation of another interest rate cut from the Federal Reserve. Jabil (JBL) emerged as the best-performing stock in the S&P 500 after announcing better-than-expected results and raising its outlook following a restructuring plan. Nvidia (NVDA) shares rebounded from recent losses due to a positive report on the chipmaker’s
Top Stock Movers: Jabil, Nvidia, General Mills, and Market Trends Read More »
Key Takeaways: Nuclear power startup Oklo announced a partnership with data center provider Switch on Wednesday. The news initially sent Oklo stock higher, but it cooled in late-morning trading. The two sides reached a ‘framework’ agreement for Oklo to provide 12 gigawatts of power to Switch’s data centers over the next two decades. The deal
Oklo Stock Fluctuates After Switch Partnership Announcement Read More »
Heico reported record-breaking revenue, net income, and operating income in the fourth quarter, yet its overall sales fell short of expectations, causing a drop in share prices. The company’s Electronic Technologies Group experienced a 2% decline in sales to $336.2 million, which was attributed to lower defense products net sales and slightly lower net sales
Heico Stock Decline Linked to Lower Electronic Technologies Sales Read More »
Jefferies has initiated a ‘buy’ rating on Rocket Pharmaceuticals. The biotech firm’s experimental gene therapies are the basis for this rating. Jefferies also set a price target of $29. The analysts are optimistic about Rocket’s treatment for a rare genetic heart condition, which they believe could be a $1 billion opportunity for the company. Shares
Rocket Pharmaceuticals Stock Surges as Jefferies Initiates ‘Buy’ Coverage Read More »
